Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Rangaswamy Govindarajan

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
DivisionInternal Med Hem-Onc
Address10-71 Cancer Institute
4104 Outpatient Circle
Mail Slot # 508
Little Rock AR 72205
Phone501-526-6990 x8046
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Rangaswamy Govindarajan is a hematologist and medical oncologist at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS) and the Central Arkansas Veterans Healthcare System (CAVHS). He is also a Professor in the UAMS Department of Internal Medicine, Division of Hematology/Oncology.Dr. Govindarajan received his medical degree from Mysore Medical College at the University of Mysore in Mysore, India. He completed an internship in General Medicine, Surgery and Ob/GYN/Pediatrics at K.R. Hospital & Cheluvamba Hospital in Mysore, India. Dr. Govindarajan completed his medical training at UAMS, first with a residency in Internal Medicine and then, as a fellow in the Division of Hematology/Oncology. He is board certified in Internal Medicine, Hematology and Oncology and is a Diplomate of the American Board of Internal Medicine.Dr. Govindarajan is a member of the American Society of Hematology and the American Society of Clinical Oncology. His primary clinical and research interests are gastrointestinal cancers, sarcoma and melanoma.


    Collapse Research 
    Collapse research activities and funding
    A021806     (GOVINDARAJAN, RANGASWAMY)Oct 22, 2021 - Oct 21, 2031
    Alliance for Clinical Trials in Oncology
    A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER (273375)
    Role: Principal Investigator
    QBGJ398     (GOVINDARAJAN, RANGASWAMY)Oct 30, 2020 - Oct 29, 2021
    QED Therapeutics, Inc.
    A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial
    Role: Principal Investigator
    QBGJ398-301     (GOVINDARAJAN, RANGASWAMY)Oct 30, 2020 - Oct 29, 2021
    QED Therapeutics, Inc.
    A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial
    Role: Principal Investigator
    A021703     (GOVINDARAJAN, RANGASWAMY)May 20, 2020
    NIH/Nat. Cancer Institute - Pass Through: Alliance for Clinical Trials in Oncology
    No FP attached
    Role: Principal Investigator
    S1815     (GOVINDARAJAN, RANGASWAMY)Oct 8, 2019
    NIH/Nat. Cancer Institute - Pass Through: SouthWest Oncology Group
    S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (IRB 239746)
    Role: Principal Investigator
    EA2165     (GOVINDARAJAN, RANGASWAMY)Sep 20, 2019
    NIH/Nat. Cancer Institute - Pass Through: ECOG-ACRIN Cancer Research Group
    No FP attached
    Role: Principal Investigator
    SWOG 1320     (GOVINDARAJAN, RANGASWAMY)Apr 24, 2015
    NIH/Nat. Cancer Institute - Pass Through: Oregon Health & Science University
    No FP attached
    Role: Principal Investigator
    SWOG1320     (GOVINDARAJAN, RANGASWAMY)Apr 24, 2015
    NIH/Nat. Cancer Institute - Pass Through: Oregon Health & Science University
    SWOG 1320, A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) And Trametininb (NSC-763093) in BRAFV600E/K MUTANT MELANOMA
    Role: Principal Investigator
    CLEE11XUS03     (GOVINDARAJAN, RANGASWAMY)Jan 12, 2015 - Dec 31, 2017
    Novartis Pharmaceuticals Corporation
    No FP attached
    Role: Principal Investigator
    E1912     (GOVINDARAJAN, RANGASWAMY)Oct 30, 2014
    NIH/Nat. Cancer Institute - Pass Through: Eastern Cooperative Oncology Group
    No FP attached
    Role: Principal Investigator
    E3311     (VURAL, EMRE)May 12, 2014
    NIH/Nat. Cancer Institute - Pass Through: Eastern Cooperative Oncology Group
    No FP attached
    Role: Principal Investigator
    CALGB 80803     (GOVINDARAJAN, RANGASWAMY)Nov 27, 2012
    NIH/Nat. Cancer Institute - Pass Through: Cancer and Leukemia Group B
    Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer (CALGB 80803)
    Role: Principal Investigator
    CALGB80803     (GOVINDARAJAN, RANGASWAMY)Nov 27, 2012
    NIH/Nat. Cancer Institute - Pass Through: Cancer and Leukemia Group B
    Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer (CALGB 80803)
    Role: Principal Investigator
    Oncotype X     (GOVINDARAJAN, RANGASWAMY)Jun 26, 2012
    Genomic Health
    Genetic Analysis to Evaluate the Racial Difference in the Outcome of Patients with Colon Cancer
    Role: Principal Investigator
    OncotypeX     (GOVINDARAJAN, RANGASWAMY)Jun 26, 2012
    Genomic Health
    Genetic Analysis to Evaluate the Racial Difference in the Outcome of Patients with Colon Cancer
    Role: Principal Investigator
    ET743-SAR     (GOVINDARAJAN, RANGASWAMY)Jan 27, 2012
    Janssen Research & Development, LLC
    A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated
    Role: Principal Investigator
    ET743-SAR-3007     (GOVINDARAJAN, RANGASWAMY)Jan 27, 2012
    Janssen Research & Development, LLC
    A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated
    Role: Principal Investigator
    CALGB 30801     (GOVINDARAJAN, RANGASWAMY)Dec 21, 2011
    NIH/Nat. Cancer Institute - Pass Through: Cancer and Leukemia Group B
    CALGB 30801 A RANDOMIZED PHASE III DOUBLE BLIND TRIAL EVALUATING SELECTIVE COX-2 INHIBITION IN COX-2 EXPRESSING ADVANCED NON-SMALL CELL LUNG CANCER
    Role: Principal Investigator
    CALGB30801     (GOVINDARAJAN, RANGASWAMY)Dec 21, 2011
    NIH/Nat. Cancer Institute - Pass Through: Cancer and Leukemia Group B
    CALGB 30801 A RANDOMIZED PHASE III DOUBLE BLIND TRIAL EVALUATING SELECTIVE COX-2 INHIBITION IN COX-2 EXPRESSING ADVANCED NON-SMALL CELL LUNG CANCER
    Role: Principal Investigator
    CALGB 30610     (GOVINDARAJAN, RANGASWAMY)Dec 20, 2011
    NIH/Nat. Cancer Institute - Pass Through: Cancer and Leukemia Group B
    CALGB 30610 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etopos
    Role: Principal Investigator
    CALGB30610     (GOVINDARAJAN, RANGASWAMY)Dec 20, 2011
    NIH/Nat. Cancer Institute - Pass Through: Cancer and Leukemia Group B
    CALGB 30610 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etopos
    Role: Principal Investigator
    N0923     (GOVINDARAJAN, RANGASWAMY)Nov 15, 2011
    NIH/Nat. Cancer Institute - Pass Through: Cancer Trials Support Unit
    CTSU N0923 A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreducti
    Role: Principal Investigator
    E1609     (GOVINDARAJAN, RANGASWAMY)Oct 25, 2011
    NIH/Nat. Cancer Institute - Pass Through: Eastern Cooperative Oncology Group
    ECOG 1609 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy
    Role: Principal Investigator
    CTSU E2108     (GOVINDARAJAN, RANGASWAMY)Oct 11, 2011
    NIH/Nat. Cancer Institute - Pass Through: Eastern Cooperative Oncology Group
    CTSU ECOG 2108, A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cance
    Role: Principal Investigator
    CTSUE2108     (GOVINDARAJAN, RANGASWAMY)Oct 11, 2011
    NIH/Nat. Cancer Institute - Pass Through: Eastern Cooperative Oncology Group
    CTSU ECOG 2108, A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cance
    Role: Principal Investigator
    CTSU No949     (GOVINDARAJAN, RANGASWAMY)May 24, 2011
    NIH/Nat. Cancer Institute - Pass Through: Cancer Trials Support Unit
    CTSU N0949 Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First
    Role: Principal Investigator
    CTSUNo949     (GOVINDARAJAN, RANGASWAMY)May 24, 2011
    NIH/Nat. Cancer Institute - Pass Through: Cancer Trials Support Unit
    CTSU N0949 Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First
    Role: Principal Investigator
    PICASSO III     (GOVINDARAJAN, RANGASWAMY)Jan 31, 2011
    Ziopharm, Inc.
    A Phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus
    Role: Principal Investigator
    PICASSOIII     (GOVINDARAJAN, RANGASWAMY)Jan 31, 2011
    Ziopharm, Inc.
    A Phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus
    Role: Principal Investigator
    CALGB 90802     (GOVINDARAJAN, RANGASWAMY)Jan 4, 2011
    NIH/Nat. Cancer Institute - Pass Through: Cancer and Leukemia Group B
    RANDOMIZED PHASE III TRIAL COMPARING EVEROLIMUS PLUS PLACEBO VERSUS EVEROLIMUS PLUS BEVACIZUMAB FOR ADVANCED RENAL CELL CARCINOMA PROGRESSING AFTER TR
    Role: Principal Investigator
    CALGB90802     (GOVINDARAJAN, RANGASWAMY)Jan 4, 2011
    NIH/Nat. Cancer Institute - Pass Through: Cancer and Leukemia Group B
    RANDOMIZED PHASE III TRIAL COMPARING EVEROLIMUS PLUS PLACEBO VERSUS EVEROLIMUS PLUS BEVACIZUMAB FOR ADVANCED RENAL CELL CARCINOMA PROGRESSING AFTER TR
    Role: Principal Investigator
    CALGB 1208     (GOVINDARAJAN, RANGASWAMY)Nov 16, 2010
    NIH/Nat. Cancer Institute - Pass Through: Cancer Trials Support Unit
    CTSU CALGB E1208 A Phase III Randomized, Double-Blind Trial of Chemoembolization
    Role: Principal Investigator
    CALGB1208     (GOVINDARAJAN, RANGASWAMY)Nov 16, 2010
    NIH/Nat. Cancer Institute - Pass Through: Cancer Trials Support Unit
    CTSU CALGB E1208 A Phase III Randomized, Double-Blind Trial of Chemoembolization
    Role: Principal Investigator
    CALGB 90601     (GOVINDARAJAN, RANGASWAMY)Sep 7, 2010
    NIH/Nat. Cancer Institute - Pass Through: Cancer Trials Support Unit
    CTSU CALGB 90601 A Randomized Doble-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab (IND #7921, NSC #704865) to Gemcitabine,
    Role: Principal Investigator
    CALGB90601     (GOVINDARAJAN, RANGASWAMY)Sep 7, 2010
    NIH/Nat. Cancer Institute - Pass Through: Cancer Trials Support Unit
    CTSU CALGB 90601 A Randomized Doble-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab (IND #7921, NSC #704865) to Gemcitabine,
    Role: Principal Investigator
    Z6051     (GOVINDARAJAN, RANGASWAMY)Sep 7, 2010
    NIH/Nat. Cancer Institute
    CTSU ACOSOG Z6051 A Phase III Prospective Randomized Trial Comparing Laparoscopic-assisted Resuction Versus Open Resection for Rectal Cancer CFDA 93.3
    Role: Principal Investigator
    VGFT-ST     (GOVINDARAJAN, RANGASWAMY)Jul 21, 2010
    Regeneron Pharmaceuticals
    A Phase 1/2 Study of Aflibercept Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Carcinoma
    Role: Principal Investigator
    VGFT-ST-0708     (GOVINDARAJAN, RANGASWAMY)Jul 21, 2010
    Regeneron Pharmaceuticals
    A Phase 1/2 Study of Aflibercept Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Carcinoma
    Role: Principal Investigator
    GIDEON     (GOVINDARAJAN, RANGASWAMY)Jun 10, 2009 - Jun 9, 2014
    Baxter Healthcare Corporation
    Global Investigation of Therapeutic Decisions in Hepatocellular carcinoma and Of itsTreatment with SorafeNib
    Role: Principal Investigator
    AP23573     (GOVINDARAJAN, RANGASWAMY)Sep 2, 2008 - Sep 1, 2013
    Merck & Company, Inc.
    A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients with Metastatic Soft Tissue or Bo
    Role: Principal Investigator
    WO#1; UARK2006-47; Protocol EFC6193     (GOVINDARAJAN, RANGASWAMY)Sep 17, 2007 - Sep 17, 2010
    Sanofi-Aventis
    A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combinatio
    Role: Principal Investigator
    EN3267     (GOVINDARAJAN, RANGASWAMY)Aug 1, 2006 - Aug 1, 2009
    Endo Pharmaceuticals
    A Multiple-Dose, Non-Randomized, Open-Label, Multicenter Study to Evaluate the Long-Term Safety and Effectiveness of EN3267 in the Treatment of Breakt
    Role: Principal Investigator
    EN3267-007 UARK 2005-34     (GOVINDARAJAN, RANGASWAMY)Aug 1, 2006 - Aug 1, 2009
    Endo Pharmaceuticals
    A Multiple-Dose, Non-Randomized, Open-Label, Multicenter Study to Evaluate the Long-Term Safety and Effectiveness of EN3267 in the Treatment of Breakt
    Role: Principal Investigator
    2004-44 G-0029 CTA     (GOVINDARAJAN, RANGASWAMY)May 20, 2005 - May 7, 2009
    Cell Genesys, Inc
    UARK 2004-44 (CGI G-0029): A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic H
    Role: Principal Investigator
    2004-40 PRN 28850 CTA     (GOVINDARAJAN, RANGASWAMY)Jan 21, 2005 - Jan 21, 2007
    Amgen, Inc.
    UARK 2004-40: A Companion Protocol for Biomarker Development and Pharmacogenetic Analysis in Subjects Enrolled in Clinical Therapeutic Trials Using Pa
    Role: Principal Investigator
    2004-35 PRN 28848 CTA     (GOVINDARAJAN, RANGASWAMY)Jan 10, 2005 - Jan 10, 2007
    Amgen, Inc.
    UARK 2004-35: A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Whose Tumors Expres
    Role: Principal Investigator
    2004     (GOVINDARAJAN, RANGASWAMY)Dec 28, 2004 - Dec 28, 2007
    Amgen, Inc.
    UARK 2004-36 (20030167): A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer followin
    Role: Principal Investigator
    2004-36 20030167 CTA     (GOVINDARAJAN, RANGASWAMY)Dec 28, 2004 - Dec 28, 2007
    Amgen, Inc.
    UARK 2004-36 (20030167): A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer followin
    Role: Principal Investigator
    UARK 2002-17     (GOVINDARAJAN, RANGASWAMY)Jul 1, 2002 - Jul 1, 2004
    Upjohn, Inc.
    UARK 2002-17 A Phase II, Randomized, Open-Label, Controlled, Dose-Evaluation, Multicenter Trial of Thalidomide for the Prevention of Diarrhea Associat
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 10; 26(10):1564-1568. PMID: 33020646.
      View in: PubMed
    2. Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WD. Incidence and Management of Olaratumab Infusion-Related Reactions. J Oncol Pract. 2019 11; 15(11):e925-e933. PMID: 31268811.
      View in: PubMed
    3. Govindarajan R, Gujja S, Siegel ER, Batra A, Saeed A, Lai K, James JD, Fogel BJ, Williamson S. Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer. Am J Clin Oncol. 2018 07; 41(7):638-642. PMID: 27849650.
      View in: PubMed
    4. Govindarajan R, Posey J, Chao CY, Lu R, Jadhav T, Javed AY, Javed A, Mahmoud FA, Osarogiagbon RU, Manne U. A comparison of 12-gene colon cancer assay gene expression in African American and Caucasian patients with stage II colon cancer. BMC Cancer. 2016 06 18; 16:368. PMID: 27316467.
      View in: PubMed
    5. Kaur H, Sasapu A, Ramos J, Govindarajan R. An Unusual Case of Gastric Cancer with Bone Marrow Metastases and Embolic Phenomena as Initial Presentation. J Gastrointest Cancer. 2015 Dec; 46(4):413-6. PMID: 25859839.
      View in: PubMed
    6. Xiang Z, Abdallah AO, Govindarajan R, Mehta P, Emanuel PD, Papenhausen P, Schichman SA. MYC amplification in multiple marker chromosomes and EZH2 microdeletion in a man with acute myeloid leukemia. Cancer Genet. 2015 Mar; 208(3):96-100. PMID: 25800664.
      View in: PubMed
    7. Kaur V, Mehta P, Johnsurd J, Govindarajan R. Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia. Blood. 2014 Nov 27; 124(23):3503-5. PMID: 25431479.
      View in: PubMed
    8. Govindarajan R, Siegel E, Makhoul I, Williamson S. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma. Am J Clin Oncol. 2013 Jun; 36(3):254-7. PMID: 22643560.
      View in: PubMed
    9. Dorroh S, Siegel E, Govindarajan R. Oral (O) versus intravenous (IV) etoposide and platinum in the treatment of extensive-stage small cell lung cancer (SCLC). 2013.
    10. Batra A, Siegel E, Govindarajan R. The influence of human papilloma virus (HPV) infection on the outcome of subjects with anal squamous cell carcinoma. ASCO Annual Meeting. 2013.
    11. Bansal M, Agarwal A, Bariola R, Aduli F, Govindarajan R. Biliary Actinomycosis Mimicking a Klatskin Tumor. J Gastrointest Cancer. 2012 Sep; 43 Suppl 1:S101-3. PMID: 21766219.
      View in: PubMed
    12. Bansal M, Agarwal A, Govindarajan R. Ectopic Adrenocorticotropic Hormone Syndrome Due to a Pancreatic Neuroendocrine Tumor. J Gastrointest Cancer. 2012.
    13. Khan MA, Holt AE, Gujja S, Govindarajan R. Utilization of bone densitometry and administration of bisphosphonates to prevent osteoporosis in patients with nonmetastatic prostate cancer receiving anti-androgen therapy. 2012.
    14. El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, Govindarajan R, Eng C, Blanke CD. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012 Aug; 30(4):1646-51. PMID: 21748296.
      View in: PubMed
    15. Bansal M, Agarwal A, Bariola R, Aduli F, Govindarajan R. Biliary Actinomycosis Mimicking a Klatskin Tumor. J Gastrointest Cancer. 2011.
    16. Kiwan E, Makhoul I, Siegel E, Hutchins L, Maddox AM, Govindarajan R, Safar AM. Cetuximab-related first infusion reaction rate in cancer patients. American Society for Clinical Oncology Annual meeting. 2011.
    17. Kunthur A, Aldwairi A, Simmen F, Govindarajan R. Effect of Metformin alone and in combination with 5-fluorouracil (5FU), Oxaliplatin (O) and iriniotecan (I) on human colon cancer cell lines. J Clin Oncol. 2011.
    18. Bansal M, Siegel E, Govindarajan R. The effect of metformin (M) on overall survival (OS) of patients (Pts) with colorectal cancer (CRC) treated with chemotherapy (CTX). 2011.
    19. Gray T, Siegel E, Govindarajan R. Impact of antidiabetic agents on the survival of subjects with colorectal cancer (CRC). 2010.
    20. Kunther A, Siegel E, Govindarajan R. Influence of thiozolidinediones (TZD) exposure on the progression of oral leukoplakia(L) and erythroplakia (E) to the development of head and neck cancer (HNC). 2010.
    21. Govindarajan R, Siegel E, Makhoul I, Williamson S. Phase II study of Bevacizumab and Erlotinib in previously untreated hepatocellular carcinoma (HCC). 2010.
    22. Raval GG, Govindarajan R. Efficacy and safety of administration of gemcitabine and docetaxel with radiation therapy in patients with high-grade soft tissue sarcoma. 2009; suppl; abstr e21503.
    23. Govindarajan R, Siegel E, Makhoul I, Williamscon S. Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hapatocellular carcinoma (HCC). 2009; suppl; abstr e15557.
    24. Govindarajan R, Siegel E, Makhoul I, Williamson S. Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hapatocellular carcinoma (HCC). Annual Gastrointestinal Cancers Symposium. 2009.
    25. Gentry RW, Spencer H, Dykstra-Long G, Govindarajan R. Role of extended lymphadenectomy in colorectal cancer. 2008.
    26. Govindarajan R, Siegel ER, Simmons DL, Lang NP. Thiazolidinedione (TZD) exposure and overall survival (OS) in squamous cell carcinoma of the head and neck (SCCHN). 2008.
    27. Makhoul I, Siegel E, Hutchins L, Maddox A, Govindarajan R. Cetuximab-related first infusion reaction (FIR) in colorectal cancer (CRC) and other cancer patients. 2008.
    28. Prasad HK, Govindarajan R. Heparin-induced skin necrosis associated with thrombocytopenia and acquired protein C and protein S deficiency. Am J Hematol. 2007 Dec; 82(12):1116-7. PMID: 17722075.
      View in: PubMed
    29. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol. 2007 Apr 20; 25(12):1476-81. PMID: 17442990.
      View in: PubMed
    30. Govindarajan R, Young JW, Harless CL, Hutchins LF. Barriers to clinical trials vary according to the type of trial and the institution. J Clin Oncol. 2007 Apr 20; 25(12):1633-4; author reply 1634. PMID: 17443010.
      View in: PubMed
    31. Karri S, Govindarajan R, Bendure WB, Jackson SA, McKelvey KD. Screening and genetic counseling practices for hereditary non-polyposis colorectal cancer (HNPCC). 2007.
    32. Govindarajan R, Siegel ER, Simmons D, Lang NP. Thiazolidinediones (TZD) exposure and risk of Squamous Cell Carcinoma of Head and Neck (SCCHN). 2007.
    33. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol. 2006 Oct 01; 24(28):e48. PMID: 17008686.
      View in: PubMed
    34. Khalil O, Govindarajan R, Safar M, Hutchins L, Mehta P. Clinical trial registration and the ICMJE. JAMA. 2005 Jan 12; 293(2):157; author reply 158. PMID: 15644532.
      View in: PubMed
    35. Govindarajan R, Ratnasinghe L, Midathada M, Kim P, Darbe M, Barnhart S, Siegel E, Simmons D, Kim L, Lang N. Association between the use of thiazilidinediones and the risk of cancer in diabetic patients. 2005.
    36. Midathada M, Spencer T, Mack K, Erkman L, Govindarajan R. Influence of demographics on patient refusal to enroll into clinical trials. 2005.
    37. Govindarajan R, Shah RV, Erkman LG, Hutchins LF. Racial differences in the outcome of patients with colorectal carcinoma. Cancer. 2003 Jan 15; 97(2):493-8. PMID: 12518374.
      View in: PubMed
    38. Govindarajan R, Shah R, Erkman LG, Hutchins LF. Racial differences in the outcome of patients with metastatic colorectal carcinoma. Cancer. 2003; 97:493-498.
    39. Govindarajan R, Safar M, Maddox AM, Hutchins LF. Irinotecan and thalidomide prolong disease free and overall survival in patients with metastatic colorectal cancer. Proceedings of the American Society of Clinical Oncology. 2003.
    40. Govindarajan R. Irinotecan/thalidomide in metastatic colorectal cancer. Oncology (Williston Park). 2002 Apr; 16(4 Suppl 3):23-6. PMID: 12014864.
      View in: PubMed
    41. Govindarajan R. Current Status of Thalidomide in the treatment of Cancer (Article Review). Oncology. 2001.
    42. Shah R, Parrish R, Coke P, Coffey M, Hathcock DC, Govindarajan R. Race and outcome of colorectal cancer in an equal access healthcare system. 2001.
    43. Govindarajan R. Thalidomide protects against the toxicity of Irinotecan. 2001.
    44. Govindarajan R. Thalidomide in Colorectal Cancer. Supplement to Oncology. 2000; 14(12 Suppl 13):29-32.
    45. Shah R, Spencer H, Erkman L, Govindarajan R. Race, Sex, and Survival among patients with Colon Cancer. Proceedings of American Society of Clinical Oncology 259a. 2000.
    46. Govindarajan R, Baxter D, Wilson C, Zent C. Vancomycin-induced thrombocytopenia. Am J Hematol. 1999; 62(2):122 - 123.
    47. Govindarajan R, Spencer T, Erkman L, Lang N. Influence of Demographic Characteristics in Rectal Carcinoma. 1999.
    48. Govindarajan R, Marshall BA, Anaissie EJ, Tyler LN, Abulezz SA. Response to Plasmapheresis in patients with Post-transplant Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome. in. 1999.
    49. Kralovics R, Hou X, Govindarajan R, Prchal JT. Autosomal Familial Polycythemia Vera mimicking Familial Thrombocytosis. Blood, 94, 10, Suppl. 1 part 1:113a. 1999.
    50. Munshi NK, Anaissie E, Drach BJ, Ayers D, Govindarajan R, Sawyer J, Shaughnessy J, Seigel D, Desikan R, Seigel S, Mehta J, Barlogie B. MDS - associated cytogenetic abnormalities in both hematopoeitic and neoplastic cells after auto transplants in 868 patients with multiple myeloma. 1998.
    51. Govindarajan R, Marshall B. Transfusion Practices in a University Hospital. 1998.
    52. Govindarajan R, Macleod S, Nowell S, Lang NP. Glutathione S-Transferase Polymorphism in Lung Cancer. American Society for Clinical Oncology. 1998.
    53. Govindarajan R, Macleod S, Nowell S, Lang NP. Glutathione S-Transferase Polymorphism in lung cancer. 1998.
    54. Govindarajan R, Tricot G, Jagannath S, Flick JT, Sawyer J, Ayers D, Barlogie B. Secondary neoplasms following auto transplants for multiple myeloma. 1997.
    55. Govindarajan R, Munshi NC, McDermott M, Erkman L, Ross SE. Environmental factors may lead to second primary malignancies in veteran population. 1997.
    56. Govindarajan R, Dhodapkar M, Munshi NC, Ross SW. Impact of prior malignancies on prognosis of resectable non small cell lung cancer. 1996.
    57. Ennist DL, Kikuchi G, Cohen R, Govindarajan R, Munshi NC, McCarty GJ, Chiang YL. Development of models to analyze the use of herpes simplex thymidine kinase (TK) in the control of graft vs. host disease (GVHD). 1996.
    58. Govindarajan R, Broadwater R, Maners A, Hutchins LF. Hepatic Arterial infusion (HAI) of cisplatin and adriamycin with whole liver radiation induces sustained remission in unresectable hepatocellular carcinoma (HCC). 1996.
    59. Govindarajan R, Et al. High incidence of second primary malignancy in veteran population. 1995.
    60. Govindarajan R, Galpin OP. Coexistence of Addison's disease, ulcerative colitis, hypothyroidism and pernicious anemia. J Clin Gastroenterol. 1992; 15(1):82 - 83.
    61. Govindarajan R, Mehta BC. Beta thalassemia carriers and iron status among cases of mild anemia (Oral Presentation). 1985.
    62. Govindarajan R, Chitnis, AS, Kakkar, V. Acquired hypoplastic emphysema of childhood. Bulletin of Jaslok Hospital & Research Center. 1983; 8(2):76.
    63. Kothari, SS, Govindarajan R, Chandalia, HB. Pseudoachondroplastic spondyloepiphyseal dysplasia. Bulletin of Jaslok Hospital & Research Center. 1983; 8(1):33.
    64. Mehta, B.C., Govindarajan R. Beta Thalassemia carriers and iron status amongst cases of mild anemia. IRCS Med. Sci. 1983; 11:539.
    Govindarajan's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (127) concept(s)
    _
    Co-Authors Expand Description
    See all (1) people
    _
    Similar People Expand Description
    See all (32) people
    _
    Same Department Expand Description
    Search Department